[8-K] Compass Therapeutics, Inc. Reports Material Event
Compass Therapeutics furnished a Current Report on Form 8-K announcing that it issued a press release with financial results for the quarter and six months ended June 30, 2025. The press release is included as Exhibit 99.1. The company also furnished the slides presented on its second quarter earnings call as Exhibit 99.2 and its August 2025 corporate presentation as Exhibit 99.3. The filing states that the materials in Item 7.01 (including Exhibit 99.2) are being furnished and not filed, and thus are not subject to Section 18 liabilities or automatically incorporated by reference in other filings. The report discloses the company's common stock trades under the symbol CMPX on the NASDAQ Capital Market. No financial figures are included within the 8-K itself; detailed results are provided in the furnished press release.
Compass Therapeutics ha presentato un Current Report sul Form 8-K annunciando di aver diffuso un comunicato stampa con i risultati finanziari per il trimestre e i sei mesi chiusi il 30 giugno 2025. Il comunicato 猫 allegato come Exhibit 99.1. La societ脿 ha inoltre fornito le slide presentate nella conference call sugli utili del secondo trimestre come Exhibit 99.2 e la presentazione aziendale di agosto 2025 come Exhibit 99.3. Il deposito specifica che i materiali dell'Item 7.01 (incluso Exhibit 99.2) sono forniti e non depositati, e pertanto non sono soggetti alle responsabilit脿 previste dalla Section 18 n茅 vengono automaticamente incorporati per riferimento in altri documenti depositati. Il rapporto indica che le azioni ordinarie della societ脿 sono negoziate con il simbolo CMPX sul NASDAQ Capital Market. Nell'8-K non sono presenti cifre finanziarie; i risultati dettagliati sono riportati nel comunicato fornito.
Compass Therapeutics present贸 un Current Report en el Form 8-K anunciando que emiti贸 un comunicado de prensa con los resultados financieros del trimestre y de los seis meses terminados el 30 de junio de 2025. El comunicado se incluye como Exhibit 99.1. La compa帽铆a tambi茅n present贸 las diapositivas mostradas en su llamada de resultados del segundo trimestre como Exhibit 99.2 y su presentaci贸n corporativa de agosto de 2025 como Exhibit 99.3. La presentaci贸n se帽ala que los materiales del 铆tem 7.01 (incluido Exhibit 99.2) est谩n proporcionados y no presentados, por lo que no est谩n sujetos a las responsabilidades de la Section 18 ni se incorporan autom谩ticamente por referencia en otros documentos. El informe revela que las acciones ordinarias de la compa帽铆a cotizan bajo el s铆mbolo CMPX en el NASDAQ Capital Market. El 8-K en s铆 no incluye cifras financieras; los resultados detallados aparecen en el comunicado proporcionado.
Compass Therapeutics電� Current Report on Form 8-K毳� 鞝滌稖頃橂┌ 2025雲� 6鞗� 30鞚� 膦呺霅� 攵勱赴 氚� 氚橁赴 鞛鞁れ爜鞚� 雼挫潃 氤措弰鞛愲毳� 氚滍憸頄堧嫟瓿� 氚濏様鞀惦媹雼�. 頃措嫻 氤措弰鞛愲電� Exhibit 99.1搿� 韽暔霅橃柎 鞛堨姷雼堧嫟. 須岇偓電� 霕愴暅 2攵勱赴 鞁れ爜 氚滍憸 旖滌棎靹� 靷毄霅� 鞀澕鞚措摐毳� Exhibit 99.2搿�, 2025雲� 8鞗� 旮办梾 頂勲爤鞝犿厡鞚挫厴鞚� Exhibit 99.3搿� 鞝滉车頄堨姷雼堧嫟. 鞝滌稖靹滌棎電� Item 7.01鞚� 鞛愲(氚� Exhibit 99.2)臧赌 鞝滉车霅� 瓴冹澊氅� 鞝涤稖霅� 瓴冹澊 鞎勲媹氙�搿� Section 18鞚� 毂呾瀯 雽�靸侅澊 鞎勲媹瓿� 雼るジ 鞝滌稖靹滊鞐� 鞛愲彊鞙茧 彀胳“ 韱淀暕霅橃 鞎婋姅雼り碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 氤搓碃靹滌棎電� 須岇偓鞚� 氤错喌欤缄皜 NASDAQ Capital Market鞐愳劀 CMPX 旮绊樃搿� 瓯半灅霅滊嫟電� 靷嫟鞚� 瓿店皽霅橃柎 鞛堨姷雼堧嫟. 8-K 鞛愳泊鞐愲姅 鞛 靾橃箻臧� 韽暔霅橃柎 鞛堨 鞎婌溂氅�, 靸侅劯頃� 瓴瓣臣電� 鞝滉车霅� 氤措弰鞛愲鞐� 旮办灛霅橃柎 鞛堨姷雼堧嫟.
Compass Therapeutics a d茅pos茅 un Current Report sur le Form 8-K annon莽ant qu'elle avait publi茅 un communiqu茅 de presse pr茅sentant les r茅sultats financiers pour le trimestre et les six mois clos le 30 juin 2025. Le communiqu茅 est joint en tant que Exhibit 99.1. La soci茅t茅 a 茅galement fourni les diapositives pr茅sent茅es lors de sa conf茅rence sur les r茅sultats du deuxi猫me trimestre en tant que Exhibit 99.2 et sa pr茅sentation corporate de ao没t 2025 en tant que Exhibit 99.3. Le d茅p么t pr茅cise que les documents figurant 脿 l'Item 7.01 (y compris Exhibit 99.2) sont fournis et non 诲茅辫辞蝉茅蝉, et ne sont donc pas soumis aux responsabilit茅s pr茅vues par la Section 18 ni incorpor茅s automatiquement par r茅f茅rence dans d'autres d茅p么ts. Le rapport mentionne que les actions ordinaires de la soci茅t茅 sont n茅goci茅es sous le symbole CMPX sur le NASDAQ Capital Market. Le 8-K lui鈥憁锚me ne contient pas de chiffres financiers ; les r茅sultats d茅taill茅s sont inclus dans le communiqu茅 fourni.
Compass Therapeutics hat einen Current Report auf Form 8-K eingereicht und mitgeteilt, dass es eine Pressemitteilung mit den Finanzergebnissen f眉r das Quartal und die sechs Monate zum 30. Juni 2025 herausgegeben hat. Die Pressemitteilung ist als Exhibit 99.1 beigef眉gt. Das Unternehmen stellte au脽erdem die in der Ergebnis-Telefonkonferenz des zweiten Quartals gezeigten Folien als Exhibit 99.2 sowie die Unternehmenspr盲sentation vom August 2025 als Exhibit 99.3 zur Verf眉gung. Die Einreichung weist darauf hin, dass die Materialien in Punkt 7.01 (einschlie脽lich Exhibit 99.2) bereitgestellt und nicht eingereicht wurden und daher nicht den Haftungsbestimmungen von Section 18 unterliegen und nicht automatisch in andere Einreichungen durch Verweis aufgenommen werden. Der Bericht gibt an, dass die Stammaktien des Unternehmens unter dem K眉rzel CMPX am NASDAQ Capital Market gehandelt werden. Im 8-K selbst sind keine finanziellen Zahlen enthalten; detaillierte Ergebnisse finden sich in der bereitgestellten Pressemitteilung.
- Press release furnished as Exhibit 99.1 announcing quarter and six-month results for the period ended June 30, 2025
- Earnings call slides and corporate presentation furnished as Exhibits 99.2 and 99.3, providing investor presentation materials
- No financial figures or operational metrics are included in the 8-K text; investors must review Exhibit 99.1 for results
- Item 7.01 materials are furnished, not filed, meaning they are not subject to Section 18 liability and are not automatically incorporated by reference into other filings
Insights
TL;DR: Routine earnings disclosure furnished via Form 8-K; investors must consult the press release for the actual financial metrics.
The filing primarily notifies investors that Compass Therapeutics has released its quarterly and six-month financial results and provided accompanying presentation slides. The 8-K furnishes Exhibits 99.1 through 99.3 and an Inline XBRL cover page, but does not itself present income statement, balance sheet, or cash flow figures. The explicit statement that Item 7.01 materials are furnished, not filed, limits their regulatory incorporation and Section 18 liability. For valuation or performance analysis, the press release and slides must be reviewed directly.
TL;DR: Procedural disclosure consistent with Reg FD and standard 8-K practice; material content resides in the exhibits rather than the filing text.
The document follows conventional governance practice by furnishing earnings communications and investor presentation materials as exhibits. Notably, the company marks the Item 7.01 content as furnished rather than filed, which is an explicit legal distinction reducing the risk of retroactive liability under Section 18. The filing confirms exchange listing and emerging growth status checkbox but contains no executive changes, material transactions, or legal disclosures. Materiality for investors depends on the numerical results in Exhibit 99.1, which are not reproduced in this report.
Compass Therapeutics ha presentato un Current Report sul Form 8-K annunciando di aver diffuso un comunicato stampa con i risultati finanziari per il trimestre e i sei mesi chiusi il 30 giugno 2025. Il comunicato 猫 allegato come Exhibit 99.1. La societ脿 ha inoltre fornito le slide presentate nella conference call sugli utili del secondo trimestre come Exhibit 99.2 e la presentazione aziendale di agosto 2025 come Exhibit 99.3. Il deposito specifica che i materiali dell'Item 7.01 (incluso Exhibit 99.2) sono forniti e non depositati, e pertanto non sono soggetti alle responsabilit脿 previste dalla Section 18 n茅 vengono automaticamente incorporati per riferimento in altri documenti depositati. Il rapporto indica che le azioni ordinarie della societ脿 sono negoziate con il simbolo CMPX sul NASDAQ Capital Market. Nell'8-K non sono presenti cifre finanziarie; i risultati dettagliati sono riportati nel comunicato fornito.
Compass Therapeutics present贸 un Current Report en el Form 8-K anunciando que emiti贸 un comunicado de prensa con los resultados financieros del trimestre y de los seis meses terminados el 30 de junio de 2025. El comunicado se incluye como Exhibit 99.1. La compa帽铆a tambi茅n present贸 las diapositivas mostradas en su llamada de resultados del segundo trimestre como Exhibit 99.2 y su presentaci贸n corporativa de agosto de 2025 como Exhibit 99.3. La presentaci贸n se帽ala que los materiales del 铆tem 7.01 (incluido Exhibit 99.2) est谩n proporcionados y no presentados, por lo que no est谩n sujetos a las responsabilidades de la Section 18 ni se incorporan autom谩ticamente por referencia en otros documentos. El informe revela que las acciones ordinarias de la compa帽铆a cotizan bajo el s铆mbolo CMPX en el NASDAQ Capital Market. El 8-K en s铆 no incluye cifras financieras; los resultados detallados aparecen en el comunicado proporcionado.
Compass Therapeutics電� Current Report on Form 8-K毳� 鞝滌稖頃橂┌ 2025雲� 6鞗� 30鞚� 膦呺霅� 攵勱赴 氚� 氚橁赴 鞛鞁れ爜鞚� 雼挫潃 氤措弰鞛愲毳� 氚滍憸頄堧嫟瓿� 氚濏様鞀惦媹雼�. 頃措嫻 氤措弰鞛愲電� Exhibit 99.1搿� 韽暔霅橃柎 鞛堨姷雼堧嫟. 須岇偓電� 霕愴暅 2攵勱赴 鞁れ爜 氚滍憸 旖滌棎靹� 靷毄霅� 鞀澕鞚措摐毳� Exhibit 99.2搿�, 2025雲� 8鞗� 旮办梾 頂勲爤鞝犿厡鞚挫厴鞚� Exhibit 99.3搿� 鞝滉车頄堨姷雼堧嫟. 鞝滌稖靹滌棎電� Item 7.01鞚� 鞛愲(氚� Exhibit 99.2)臧赌 鞝滉车霅� 瓴冹澊氅� 鞝涤稖霅� 瓴冹澊 鞎勲媹氙�搿� Section 18鞚� 毂呾瀯 雽�靸侅澊 鞎勲媹瓿� 雼るジ 鞝滌稖靹滊鞐� 鞛愲彊鞙茧 彀胳“ 韱淀暕霅橃 鞎婋姅雼り碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 氤搓碃靹滌棎電� 須岇偓鞚� 氤错喌欤缄皜 NASDAQ Capital Market鞐愳劀 CMPX 旮绊樃搿� 瓯半灅霅滊嫟電� 靷嫟鞚� 瓿店皽霅橃柎 鞛堨姷雼堧嫟. 8-K 鞛愳泊鞐愲姅 鞛 靾橃箻臧� 韽暔霅橃柎 鞛堨 鞎婌溂氅�, 靸侅劯頃� 瓴瓣臣電� 鞝滉车霅� 氤措弰鞛愲鞐� 旮办灛霅橃柎 鞛堨姷雼堧嫟.
Compass Therapeutics a d茅pos茅 un Current Report sur le Form 8-K annon莽ant qu'elle avait publi茅 un communiqu茅 de presse pr茅sentant les r茅sultats financiers pour le trimestre et les six mois clos le 30 juin 2025. Le communiqu茅 est joint en tant que Exhibit 99.1. La soci茅t茅 a 茅galement fourni les diapositives pr茅sent茅es lors de sa conf茅rence sur les r茅sultats du deuxi猫me trimestre en tant que Exhibit 99.2 et sa pr茅sentation corporate de ao没t 2025 en tant que Exhibit 99.3. Le d茅p么t pr茅cise que les documents figurant 脿 l'Item 7.01 (y compris Exhibit 99.2) sont fournis et non 诲茅辫辞蝉茅蝉, et ne sont donc pas soumis aux responsabilit茅s pr茅vues par la Section 18 ni incorpor茅s automatiquement par r茅f茅rence dans d'autres d茅p么ts. Le rapport mentionne que les actions ordinaires de la soci茅t茅 sont n茅goci茅es sous le symbole CMPX sur le NASDAQ Capital Market. Le 8-K lui鈥憁锚me ne contient pas de chiffres financiers ; les r茅sultats d茅taill茅s sont inclus dans le communiqu茅 fourni.
Compass Therapeutics hat einen Current Report auf Form 8-K eingereicht und mitgeteilt, dass es eine Pressemitteilung mit den Finanzergebnissen f眉r das Quartal und die sechs Monate zum 30. Juni 2025 herausgegeben hat. Die Pressemitteilung ist als Exhibit 99.1 beigef眉gt. Das Unternehmen stellte au脽erdem die in der Ergebnis-Telefonkonferenz des zweiten Quartals gezeigten Folien als Exhibit 99.2 sowie die Unternehmenspr盲sentation vom August 2025 als Exhibit 99.3 zur Verf眉gung. Die Einreichung weist darauf hin, dass die Materialien in Punkt 7.01 (einschlie脽lich Exhibit 99.2) bereitgestellt und nicht eingereicht wurden und daher nicht den Haftungsbestimmungen von Section 18 unterliegen und nicht automatisch in andere Einreichungen durch Verweis aufgenommen werden. Der Bericht gibt an, dass die Stammaktien des Unternehmens unter dem K眉rzel CMPX am NASDAQ Capital Market gehandelt werden. Im 8-K selbst sind keine finanziellen Zahlen enthalten; detaillierte Ergebnisse finden sich in der bereitgestellten Pressemitteilung.
FAQ
What did Compass Therapeutics (CMPX) disclose in this Form 8-K?
Which exhibits were attached to the 8-K for CMPX?
Are the Item 7.01 materials in the CMPX 8-K considered filed with the SEC?
Does this 8-K include the company's financial statements?
What is Compass Therapeutics' ticker and exchange as stated in the filing?
